RxDoctor Payments Data

Garry Banks, MD

Internal Medicine · Niceville, FLNPI 1588631493

Payments from drug & device makers

$227,791in general payments, 2019–2025

Across 793 payments — averaging $287.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$220K
  • Amgen$2K
  • AstraZeneca$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$646
  • TELA Bio, Inc.$466
  • Novo Nordisk$392
  • plus $3K from 32 others

What the payments were for

  • Consulting fees$7,1253%
  • Speaking & faculty fees$173,70076%
  • Travel & lodging$30,05413%
  • Food & beverage$16,5587%
  • Education$3540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$227,791 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$309,282
Medicare patients
385
Services billed
8,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide74$113,209
EliquisApixaban96$99,471
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$66,091
MounjaroTirzepatide51$49,856
CreonLipase/Protease/Amylase13$38,736
XareltoRivaroxaban26$33,355
OzempicSemaglutide13$30,085
JardianceEmpagliflozin36$29,528
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$26,833
FarxigaDapagliflozin Propanediol19$25,861
Bydureon BciseExenatide Microspheres11$19,920
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$17,201
LinzessLinaclotide19$16,645
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$13,699
JanuviaSitagliptin Phosphate11$11,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$219,671$163,065125 claims
PfizerEliquis$70$99,47196 claims
GSKTrelegy Ellipta, Anoro Ellipta$154$92,92497 claims
AbbVieCreon, Linzess, Synthroid$294$57,43956 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,577$43,06333 claims
Johnson & JohnsonXarelto$373$33,35526 claims
Novo NordiskOzempic$392$30,08513 claims
Boehringer IngelheimJardiance$80$29,52836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Niceville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →